Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 10.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,250 shares of the biotechnology company’s stock after purchasing an additional 2,417 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Sarepta Therapeutics were worth $432,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in Sarepta Therapeutics during the 1st quarter worth approximately $1,458,000. Sound View Wealth Advisors Group LLC boosted its holdings in shares of Sarepta Therapeutics by 18.8% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 4,863 shares of the biotechnology company’s stock valued at $310,000 after acquiring an additional 771 shares during the last quarter. Blueshift Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics in the first quarter worth $488,000. Raiffeisen Bank International AG raised its holdings in shares of Sarepta Therapeutics by 1,092.2% during the first quarter. Raiffeisen Bank International AG now owns 17,465 shares of the biotechnology company’s stock worth $1,220,000 after purchasing an additional 16,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Sarepta Therapeutics by 3.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 646,291 shares of the biotechnology company’s stock valued at $41,246,000 after purchasing an additional 22,542 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on SRPT shares. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $19.00 to $26.00 in a research note on Wednesday, November 5th. BMO Capital Markets raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $50.00 price target for the company in a report on Monday, September 22nd. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Leerink Partners lifted their target price on shares of Sarepta Therapeutics from $12.00 to $15.00 and gave the company a “market perform” rating in a report on Tuesday, September 9th. Finally, The Goldman Sachs Group increased their price target on shares of Sarepta Therapeutics to $19.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $33.75.

Sarepta Therapeutics Stock Performance

SRPT opened at $20.95 on Thursday. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -24.08 and a beta of 0.52. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81. The firm’s fifty day simple moving average is $20.34 and its two-hundred day simple moving average is $22.33.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company had revenue of $399.36 million for the quarter, compared to analysts’ expectations of $331.51 million. During the same period in the prior year, the firm earned $0.62 EPS. The firm’s revenue for the quarter was down 14.5% on a year-over-year basis. Equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.